<DOC>
	<DOCNO>NCT00557219</DOCNO>
	<brief_summary>The purpose study compare effect fenoldopam ketanserin kidney function preservation patient high risk renal failure cardiac surgery . Acute , oliguric renal failure develop 2 % patient undergoing cardiac surgery . Some require renal replacement therapy despite mortality group exceed 30-60 % . The investigator await use fenoldopam and/or ketanserin may decrease rate severe renal failure .</brief_summary>
	<brief_title>Fenoldopam Ketanserin Acute Kidney Failure Prevention After Cardiac Surgery</brief_title>
	<detailed_description>Informed , sign consent obtain patient surgery . In patient acute consciousness disorder , consent obtain legal representative confirm local court - accordingly Polish legacy . Patients willing participate study fulfil least one two inclusion criterion randomly assign one three study group . The treatment apply 24 hour . Intention treat analysis include comparison difference continuous , homogeneous distribute data use parametric test , parametric inhomogeneous distribute data - use nonparametric test . The treatment effect assess comparison odds ratios primary secondary outcome group .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Ketanserin</mesh_term>
	<mesh_term>Fenoldopam</mesh_term>
	<criteria>cardiac surgery least one risk factor acute renal failure : 1. oliguria &lt; 0.5 ml/kg/hour 3 hour despite adequate blood volume furosemide intravenously 2. least 60 mg furosemide/12 hour iv maintain diuresis &gt; 1 ml/kg/hour refuse none consent chronic renal failure chronic renal replacement therapy chronic increase serum creatinine &gt; 2 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cardiac surgery</keyword>
	<keyword>fenoldopam</keyword>
	<keyword>ketanserin</keyword>
	<keyword>renal replacement therapy</keyword>
</DOC>